Clinical Trials Logo

Clinical Trial Summary

Indeterminate lung nodules (6-15mm) are frequent findings in patients undergoing chest CT scanning, but adequate follow-up imaging is currently not in place to facilitate early detection, diagnosis and decision making regarding treatment. The introduction of long Field-Of-View PET/CT scanners could make a difference in this matter due to the substantial increase in sensitivity allowing optimal image quality. Whether this new technology could provide improved detection and follow-up of indeterminate lung nodules is what we aim to explore in this study.


Clinical Trial Description

Indeterminate lung nodules (6-15 mm) are frequent findings in patients undergoing chest Computed Tomography (CT). In the large randomized controlled Dutch-Belgian lung cancer screening trial NELSON, overall, 9.2% of the screened participants had an initially indeterminate CT scan. To decrease mortality from lung cancer, early identification of malignant lesions among the many lung nodules is crucial. The probability of malignancy depends on size and other factors. It is difficult to determine whether a nodule is malignant on size alone. For further differentiation of a lung nodule, usually, repeated chest CT scanning is performed at 3-6 months up to 2 years to assess nodule growth, and/or 2-deoxy-2-[fluorine-18) fluoro-D-glucose (18F-FDG) Positron Emission Tomography (PET)/CT to evaluate metabolic activity. However, repetitive CT scans are not favoured because of radiation exposure, patiënt anxiety, and potential delay in cancer diagnosis. Furthermore, 18F-FDG PET/CT has thus far insufficiënt sensitivity for detection and characterization of small (in particular < 1 cm) lung nodules, meaning that a negative result does not rule out the presence of cancer, which thus usually requires further follow-up CT scans. Improvement in work-up of indeterminate lung nodules is urgently needed, in particular with the expected introduction of lung cancer screening in the coming years. In this study, the aim is to derive optimal imaging procedures and to assess the technical performance of the Vision Quadra PET/CT system concerning its feasibility to detect indeterminate lung nodules. Furthermore, this study aims to preliminary explore the sensitivity, specificity, and accuracy of the characterisation of lung nodules using the Vision Quadra PET/CT. After enrolment, patients will receive a Standard 3 MBq/kg injection of 18F-FDG and undergo whole-body dynamic PET/CT acquisition at 30-60 min post-injection (pi), followed by a 10 min whole-body list-mode PET/CT acquisition. Subsequently, patients will be asked to hold their breath for 15 seconds to assess the added value of a single fast deep-inspiration breath-hold acquisition. At 120 min pi a second 10 min whole-body list-mode PET/CT will be acquired to potentially further differentiate between inflammation and malignancy. The list-mode acquisitions can be reprocessed retrospectively with less counts to produce images representing scans collected with lower activity administration or shorter scan times (e.g., a 1 min instead of 10 min PET scan is equivalent to 10% of the injected activity at scan start). Quantitative image analysis results will be correlated with pathology (benign or malignant) of the lung lesion, and results of a previously performed routine-care 18F-FDG PET/CT and CT chest. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05463913
Study type Interventional
Source University Medical Center Groningen
Contact Adrienne H Brouwers, MD PhD
Phone +31503613093
Email a.h.brouwers@umcg.nl
Status Recruiting
Phase Phase 4
Start date July 13, 2022
Completion date December 31, 2023

See also
  Status Clinical Trial Phase
Completed NCT03918538 - A Series of Study in Testing Efficacy of Pulmonary Rehabilitation Interventions in Lung Cancer Survivors N/A
Recruiting NCT05078918 - Comprehensive Care Program for Their Return to Normal Life Among Lung Cancer Survivors N/A
Active, not recruiting NCT04548830 - Safety of Lung Cryobiopsy in People With Cancer Phase 2
Completed NCT04633850 - Implementation of Adjuvants in Intercostal Nerve Blockades for Thoracoscopic Surgery in Pulmonary Cancer Patients
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT05583916 - Same Day Discharge for Video-Assisted Thoracoscopic Surgery (VATS) Lung Surgery N/A
Completed NCT00341939 - Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
Not yet recruiting NCT06376253 - A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers Phase 1
Recruiting NCT05898594 - Lung Cancer Screening in High-risk Black Women N/A
Active, not recruiting NCT05060432 - Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT03575793 - A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer Phase 1/Phase 2
Active, not recruiting NCT03667716 - COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors. Phase 1
Terminated NCT01624090 - Mithramycin for Lung, Esophagus, and Other Chest Cancers Phase 2
Terminated NCT03275688 - NanoSpectrometer Biomarker Discovery and Confirmation Study
Not yet recruiting NCT04931420 - Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive Surgery for Patients With Metastatic Foregut Cancer and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid Levels Phase 2
Recruiting NCT06010862 - Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors Phase 1
Recruiting NCT06052449 - Assessing Social Determinants of Health to Increase Cancer Screening N/A
Not yet recruiting NCT06017271 - Predictive Value of Epicardial Adipose Tissue for Pulmonary Embolism and Death in Patients With Lung Cancer
Recruiting NCT05787522 - Efficacy and Safety of AI-assisted Radiotherapy Contouring Software for Thoracic Organs at Risk